

1 **Nutritional deficiency recapitulates intestinal injury associated with**  
2 **environmental enteric dysfunction in patient-derived Organ Chips**

3

4 Amir Bein<sup>1,13</sup>, Cicely W. Fadel<sup>1,2,13</sup>, Ben Swenor<sup>1</sup>, Wuji Cao<sup>1</sup>, Rani K. Powers<sup>1</sup>, Diogo M.  
5 Camacho<sup>1,3</sup>, Arash Naziripour<sup>1</sup>, Andrew Parsons<sup>1</sup>, Nina LoGrande<sup>1</sup>, Sanjay Sharma<sup>1</sup>, Seongmin  
6 Kim<sup>1</sup>, Sasan Jalili-Firoozinezhad<sup>1,4</sup>, Jennifer Grant<sup>1</sup>, David T. Breault<sup>2,5,6</sup>, Junaid Iqbal<sup>7</sup>, Asad Ali<sup>7</sup>,  
7 Lee A Denson<sup>8,9</sup>, Sean R. Moore<sup>10</sup>, Rachelle Prantil-Baun<sup>1</sup>, Girija Goyal<sup>1</sup>, and Donald E.  
8 Ingber<sup>1,11,12\*</sup>

9

10 <sup>1</sup>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA

11 <sup>2</sup>Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA

12 <sup>3</sup>Current address: Rheos Medicines, Cambridge, MA, USA

13 <sup>4</sup>Department of Bioengineering and iBB - Institute for Bioengineering and Biosciences, Instituto Superior  
14 Técnico, Universidade de Lisboa, Lisboa, Portugal

15 <sup>5</sup>Division of Endocrinology, Boston Children's Hospital, Boston, MA 02115, USA

16 <sup>6</sup>Harvard Stem Cell Institute, Harvard University, Boston, MA 02139, USA

17 <sup>7</sup>Department of Paediatrics and Child Health, The Aga Khan University, Karachi 74800, Pakistan

18 <sup>8</sup>Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center,  
19 Cincinnati, OH, USA.

20 <sup>9</sup>Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

21 <sup>10</sup>Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University  
22 of Virginia, Charlottesville, USA.

23 <sup>11</sup>Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge,  
24 MA 02138, USA.

25 <sup>12</sup>Vascular Biology Program and Department of Surgery, Harvard Medical School and Boston Children's  
26 Hospital, Boston, MA 02115, USA.

27 <sup>13</sup> These authors contributed equally: Amir Bein, Cicely W. Fadel

28 \*Address correspondence to: [don.ingber@wyss.harvard.edu](mailto:don.ingber@wyss.harvard.edu)

29 **ABSTRACT**

30 Environmental Enteric Dysfunction (EED) is a chronic inflammatory condition of the  
31 intestine characterized by villus blunting, compromised intestinal barrier function, and reduced  
32 nutrient absorption. Here, we show that key genotypic and phenotypic features of EED-  
33 associated intestinal injury can be reconstituted in a human intestine-on-a-chip (Intestine Chip)  
34 microfluidic culture device lined by organoid-derived intestinal epithelial cells from EED patients  
35 and cultured in niacinamide- and tryptophan-deficient (-N/-T) medium. Exposure of EED  
36 Intestine Chips to -N/-T deficiencies resulted in transcriptional changes similar to those seen in  
37 clinical EED patient samples including congruent changes in six of the top ten upregulated  
38 genes. Exposure of EED Intestine Chips or chips lined by healthy intestinal epithelium (healthy  
39 Intestine Chips) to -N/-T medium resulted in severe villus blunting and barrier dysfunction, as  
40 well as impairment of fatty acid uptake and amino acid transport. EED Intestine Chips exhibited  
41 reduced secretion of cytokines at baseline, but their production was significantly upregulated  
42 compared to healthy Intestine Chips when exposed to -N/-T deficiencies. The human Intestine  
43 Chip model of EED-associated intestinal injury may be useful for analyzing the molecular,  
44 genetic, and nutritional basis of this disease and can serve as a preclinical model for testing  
45 potential EED therapeutics.

46  
47 **INTRODUCTION**

48  
49 Environmental Enteric Dysfunction (EED) is a pediatric disorder characterized by chronic  
50 intestinal inflammation that is associated with malnutrition, stunted growth, cognitive  
51 impairment, and attenuated response to oral vaccines<sup>1-5</sup>. Previously described as “tropical  
52 enteropathy” or “environmental enteropathy”, EED has gained renewed interest in recent years

53 due to its devastating effect on millions of children in low-and middle-income countries. The  
54 intestine of EED patients commonly exhibits villous atrophy, nutrient malabsorption, barrier  
55 dysfunction, and inflammation<sup>6,7</sup>. Currently, there is limited mechanistic understanding of the  
56 disease, which has hampered efforts to define biomarkers for diagnosis and therapeutics for  
57 effective prevention or treatment<sup>8</sup>. For example, deficiencies of micronutrients, such as zinc<sup>9</sup>  
58 and vitamin A<sup>10</sup>, may contribute to EED pathophysiology as they are associated with abnormal  
59 lactulose-mannitol (L:M) ratios, a measure of intestinal permeability. However, attempts at  
60 therapeutic intervention with nutritional replenishment have been disappointing likely due to  
61 ongoing intestinal dysfunction<sup>8</sup>. Similarly, other dietary interventions, such as administering  
62 omega-3 long-chain polyunsaturated fatty acids<sup>11</sup>, optimizing amino acid profiles<sup>12</sup>,  
63 supplementing with multiple micronutrients<sup>13</sup> or improving food digestibility through  
64 fermentation, hydrolysis, or enzyme supplementation<sup>12</sup>, also have been tested with limited  
65 success.

66         Beyond its role as a major manifestation of EED, malnutrition is also likely to actively  
67 contribute to disease pathophysiology. Murine diets low in the essential amino acid tryptophan  
68 lead to decreased antimicrobial peptide secretion and increased susceptibility to chemical-  
69 induced intestinal inflammation<sup>14</sup>. Low serum tryptophan levels are also linked to stunting in  
70 children suffering from EED<sup>15,16</sup>. Tryptophan is both a building block for proteins and a  
71 precursor for niacin, melatonin, and neurotransmitters, including serotonin and tryptamine<sup>17</sup>.  
72 In animal studies, symptoms of tryptophan deficiency, including anorexia and impaired growth,  
73 may occur with intakes as little as 25% below the standard requirement, which translates to 2  
74 to 2.5 mg/kg body weight for human infants 6-24 months old<sup>17,18</sup>. Recently, niacin (nicotinic

75 acid) deficiency also has been implicated as a contributor to EED and other inflammatory  
76 intestinal conditions as administration of niacin was shown to ameliorate dextran sodium  
77 sulfate-induced colitis via prostaglandin D<sub>2</sub>-mediated D prostanoid receptor 1 activation<sup>19</sup>. In  
78 addition, niacin serves as a precursor for coenzymes, such as nicotinamide adenine dinucleotide  
79 (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are essential for the  
80 normal function and survival of living cells. However, a mechanistic role for malnutrition in  
81 driving EED pathophysiology in humans remains to be demonstrated.

82         Studying a multifactorial disease, such as EED, raises substantial methodical and  
83 modeling challenges and, at present, there are only a few murine models and no existing  
84 human *in vitro* models that can be used to study this disease<sup>20</sup>. Thus, establishing an *in vitro*  
85 human EED model would help to elucidate disease pathophysiology and enable the  
86 development of new prevention and therapeutic measures. Here, we describe how human  
87 organ-on-a-chip (Organ Chip) microfluidic culture technology that faithfully recapitulates the  
88 structure and function of many human organs, including intestine<sup>21-30</sup>, can be leveraged to  
89 meet this challenge. Our studies using human Intestine Chips lined with organoid-derived  
90 primary intestinal epithelium isolated from either healthy or EED patients presented here  
91 reveal that both nutritional deficiencies and genetic or epigenetic changes in the intestinal  
92 epithelium contribute to the clinically observed EED phenotype. Moreover, by comparing  
93 healthy and EED patient-derived Intestine Chips, we were able to study phenotypic responses  
94 to nutritional deficiencies, such as villus blunting and barrier dysfunction, which are known to  
95 be common to multiple intestinal pathologies (for example, inflammatory bowel diseases,

96 celiac), and which distinguish them from responses due to transcriptomic and cytokine  
97 signatures that are unique to EED.

98

## 99 **RESULTS**

### 100 ***Nutritionally deficient EED Chips recapitulate EED patient transcriptional signatures***

101 We previously described a two-channel, microfluidic, human Intestine Chip lined with  
102 living human intestinal epithelium isolated from patient-derived organoids that undergoes villus  
103 differentiation, accumulates mucus, and exhibits many features of living human intestine when  
104 cultured on-chip under continuous flow with peristalsis-like mechanical deformations<sup>27</sup> (**Fig.**  
105 **1a**). Additionally, transcriptional analysis demonstrated that when lined by organoid-derived  
106 duodenal epithelium, this Intestine Chip more closely mimicked *in vivo* human duodenum than  
107 the organoids used to create the chips<sup>27</sup>. To define the contribution of the intestinal epithelium  
108 to the EED phenotype, we created Intestine Chips lined with intestinal epithelial cells from  
109 organoids derived from surgical biopsies of either healthy or EED patient duodenum (Healthy  
110 Chips and EED Chips, respectively). Compared to Healthy Chips, EED Chips showed differential  
111 expression of 287 genes (FDR < 0.05 and fold change  $\geq$  1.5; 86 upregulated, 201  
112 downregulated) (**Fig. 1b**). EED chips showed upregulation of the protective mucin MUC5AC,  
113 neuregulin-4 (a known survival factor for colonic epithelium that protects against experimental  
114 intestinal injury<sup>31,32</sup>), and the intestinal stem cell marker SMOC2, whereas brush border  
115 peptidase MME, oxidative stress and inflammatory response controlling ectoenzyme VNN1,  
116 tight junction protein CLDN10, and secreted goblet cell protein CLCA1 were all down-regulated  
117 (**Supplementary Table 1**).

118 We compared this differential gene expression profile with a recently derived clinical  
119 EED signature, which was obtained by comparing profiles of intestinal tissue samples from EED  
120 patients who were refractory to nutritional intervention (Study of Environmental Enteropathy  
121 and Malnutrition, SEEM) versus samples from healthy control patients who were investigated  
122 for gastrointestinal symptoms but had normal endoscopic and histologic findings (Cincinnati  
123 Children's Hospital Medical Center)<sup>33</sup>. When we compared gene profiles from EED Chips versus  
124 Healthy Chips cultured in control medium (i.e., with all nutrients present), the differentially  
125 expressed genes had some overlap with the clinical EED signature, including most notably a  
126 shared downregulation of metallothioneins (*MT1X*, *MT1A*, *MT1F*, *MT1H*, *MSMB*, *MT1M*; gene  
127 dendrogram cluster 3) (**Fig. 1c**).

128 We then carried out the same experiment but perfused both the Healthy and EED  
129 Intestine Chips with medium deficient in niacinamide and tryptophan (-N/-T), selected based on  
130 past work implicating their role in EED<sup>15,16,19</sup>. When we compared expression profiles from the  
131 Healthy Chips exposed to nutritional deficiency (Healthy -N/-T Chip) versus the Healthy Control  
132 Chips, we detected differential expression of 690 genes (FDR < 0.05 and fold change  $\geq$  1.5; 556  
133 upregulated, 124 downregulated) (**Fig. 1b and Supplementary Fig.S1**) including upregulation of  
134 the amino acid starvation related transcription factor ATF4, its downstream solute carriers  
135 (SLC34A2, SLC7A5, SLC6A9) and the inflammation-associated gene LCN2 (**Supplementary Table**  
136 **1**). There also appeared to be a trend towards upregulation of several antimicrobial and  
137 immune response genes as seen in the clinical EED signature, but these changes did not reach  
138 statistical significance. While there was greater overlap between the transcriptome of the  
139 Healthy -N/-T Chip with the clinical EED transcriptome than observed with the EED Control Chip

140 compared to Healthy Control Chip, some genes were regulated in an opposing  
141 direction, including upregulation of metallothioneins (**Fig. 1c**, gene dendrogram cluster 3).

142 In contrast, we observed closer unsupervised hierarchical clustering with the clinical EED  
143 signature when the EED Chip was exposed to nutritional deficiency (EED -N/-T Chip vs EED  
144 Control Chip) (**Fig. 1c**). Culture of the EED Intestine Chips in -N/-T medium yielded differential  
145 expression of 969 genes (FDR < 0.05 and fold change  $\geq 1.5$ ; 522 upregulated, 447  
146 downregulated) (**Fig. 1b**). This was manifested by upregulation of antimicrobial genes (*SAA1*,  
147 *SAA2*, *DUOXA2*, *DUOX2*, *CXCL5*; gene dendrogram clusters 8, 9 and 10) and downregulation of  
148 not only metallothioneins, but also metabolic and digestive genes (*SLC26A3*, *GUC2AB*; gene  
149 dendrogram clusters 5 and 6). This congruence was most striking amongst the top ten  
150 upregulated genes of the clinical EED signature, 6 of which (60%) were also upregulated when  
151 EED Chips were exposed to nutritionally deficient medium (**Fig. 1d**). Dendrogram cluster 5 was  
152 largely incongruent with the Intestine Chip transcriptional signature and included genes  
153 predominantly expressed in nerves, muscle and extracellular matrix.

154 To identify pathways affected by exposure of EED Intestine Chips to -N/-T nutritional  
155 deficiency, we used a contextual language-processing program to identify and rank functionally  
156 related clusters of genes<sup>34</sup>. This analysis revealed several pathways that were significantly  
157 upregulated when EED Chips were exposed to -N/-T media, including chemokine pathway  
158 (score 1833.89, indicates fold enrichment over random association) and pathway associated  
159 with amino acid starvation (score 1988.09) (**Fig. 1e**). Within the amino acid starvation pathway,  
160 the ATF4 gene is upstream of several other pathways including tRNA metabolism (score  
161 1547.01), DNA damage (score 1790.28), p53 methylation (score 1608.44), and amino acid

162 transporters (score 2022.97). Many of these same pathways were also upregulated in  
163 nutritionally deficient Healthy -N/-T Chips. Conversely, nutritional deficiency led to down  
164 regulation of pathways related to fatty acid uptake (score 3590.64), brush border structural  
165 integrity (score 3777.69), mitosis (score 3311.49), cytochrome p450 (score 2581.54), and fatty  
166 acid utilization (score 2056.86) in the EED Chips. These results are consistent with the  
167 observation that the intestines of nutritionally deficient EED patients are characterized by  
168 having decreased brush border development and impaired cell growth<sup>35-37</sup>.

### 169 ***Intestinal villus atrophy and barrier compromise***

170 As the transcriptomic analysis revealed downregulation in pathways involved in cell  
171 growth and intestinal barrier formation, we carried out differential interference (DIC) and  
172 immunofluorescence microscopic analysis which indeed confirmed that both Healthy and EED  
173 Intestine Chips showed dramatically reduced growth of villus-like structures when cultured  
174 under nutrition deficient (-N/-T) conditions compared to Health and EED Control Chips perfused  
175 with complete medium (**Fig. 2a,b**). Quantification of the height of the epithelium revealed that  
176 removal of these nutrients resulted in significant villus blunting in both Healthy and EED Chips  
177 in response to -N/-T deficiency, as indicated by a 70% and 80% reduction in epithelial height,  
178 respectively, when compared to the same chips cultured in complete medium (**Fig. 2c**).

179 Another gene cluster identified as being preferentially sensitive to nutritional deficiency  
180 includes genes governing brush border structural integrity. These genes included myosin 1a  
181 (MYO1A), which links actin to the overlying apical membrane and whose absence results in  
182 irregularities of microvilli packing and length<sup>38</sup>; protocadherin-24 (CDHR2) that forms links  
183 between adjacent microvilli and is the target of enterohemorrhagic *Escherichia coli*-mediated



184 brush border damage<sup>39</sup>; and mucin-like protocadherin (CDHR5) that forms heterophilic  
185 complexes with CDHR2 (**Supplementary Fig. S2**). Indeed, scanning electron microscopic (SEM)  
186 imaging revealed that culturing healthy intestinal epithelium in -N/-T medium on-chip resulted  
187 in severe loss of apical microvilli (as well as links between adjacent microvilli) relative to control  
188 enterocytes that had their entire surface covered with tightly packed microvilli (**Supplementary**  
189 **Fig. S3**). Consistent with these findings and the observed down regulation of the MUC5AC gene,  
190 live imaging and mucus staining with fluorescent lectin revealed that both the Healthy and EED  
191 Chips exhibited a much thinner mucus layer when exposed to nutrient deficient conditions (**Fig.**  
192 **2d**).

193           Following these observations of structural changes due to exposure to nutritional  
194 deficiency, we next leveraged the advantage of using a two-channel microfluidic Intestine Chip  
195 (**Fig. 1a**) (e.g., as opposed to intestinal organoids cultured within a solid ECM gel) to assess the  
196 effect of exposure to -N/-T medium on functional differences in intestinal barrier function  
197 between Healthy and EED Chips. We compared apparent permeability ( $P_{app}$ ) values, which were  
198 measured by calculating the transfer of Cascade Blue fluorescent tracer (~550 Da) from the  
199 epithelial lumen in the top channel to the underlying parallel channel below. Both Healthy and  
200 EED Control Chips exhibited a tight barrier under baseline conditions (within the  $10^{-7}$   $P_{app}$  range)  
201 and displayed small, but statistically significant reductions in barrier function when exposed to  
202 nutritional deficiency, as indicated by 8.9- and 2.5-fold increases in  $P_{app}$  for the Healthy and EED  
203 Chips, respectively (**Fig. 2e**).

204

205

206 ***Reduced nutrient absorption***

207 Our transcriptomic analysis also revealed that nutritional deficiency resulted in down  
208 regulation of multiple genes associated with the uptake and processing of important nutritional  
209 components, including fatty acids, certain amino acids, and carbohydrates (**Fig. 1d**). This is  
210 clinically relevant because reduced absorption of nutrients is another hallmark of EED, and it  
211 affects weight and linear growth as well as cognitive development in children<sup>40-43</sup>. For example,  
212 expression levels for fatty acid translocase (CD36), microsomal triglyceride transfer protein  
213 (MTTP), apolipoprotein B (ApoB), and apolipoprotein C-III (ApoC3) were all lower in nutritionally  
214 deficient epithelium (**Fig. 3a**). Similarly, when we used immunofluorescence microscopy to  
215 assess expression of ApoB protein, which is a marker of chylomicron and fat metabolism in the  
216 intestine<sup>44</sup>, we found that exposure to -N/-T nutritional deficiency resulted in significant down  
217 regulation of ApoB in EED Intestine Chips (**Fig. 3b**). Furthermore, when we quantified cellular  
218 uptake of fatty acids using fluorescently-labelled dodecanoic acid, we found that exposure to  
219 nutritional deficiency reduced fatty acid uptake by 1.68- and 1.69-fold in Healthy -N/-T Chips  
220 and EED -N/-T Chips, respectively, compared to Healthy and EED Control Chips (**Fig. 3c**). These  
221 findings are consistent with clinical data that similarly show impaired fatty acid metabolism in  
222 children suffering from EED<sup>16</sup> and suggest that nutritional deficiency alone is sufficient to  
223 reduce fatty acid uptake even in healthy intestine.

224 ***Abnormal amino acid uptake and metabolism***

225 Children suffering from EED exhibit impaired development, and protein availability from  
226 the diet is a key factor responsible for linear growth; thus, we next explored differences in  
227 uptake by Healthy and EED Intestine Chips. In the intestine, dietary protein is broken down into

228 short peptides and free amino acids that are taken up by enterocytes, which serve as building  
229 blocks and energy sources for various organs and tissues<sup>40</sup>. Transcriptomic analysis revealed  
230 absorption and metabolizing factors that were down regulated in EED Control Chips vs Healthy  
231 Control Chips, including the solute carrier family 2 (facilitated glucose transporter) member 2  
232 (SLC2A2) and solute carrier family 2 (facilitated glucose/fructose transporter) member 5  
233 (SLC2A5). Other nutrient transporters (e.g., amino acid absorption and metabolizing factors)  
234 that were found to be significantly down regulated in EED Chips in response to -N/-T deficiency  
235 (EED -N/-T vs EED Con), include SLC36A1, which encodes the proton-coupled amino acid  
236 transporter 1, ANPEP membrane enzyme alanine aminopeptidase that is responsible for peptide  
237 digestion at the brush border, retinol binding protein 2 (RBP2), cytochrome P450, family 27,  
238 subfamily A, and polypeptide 1 (CYP27A1) (**Fig. 4a and Supplementary Fig. S4**).

239 We then assessed differences in absorption of nutrients between the Healthy and EED  
240 Intestine Chips grown in control medium by performing untargeted metabolomic analysis by  
241 liquid chromatography tandem mass spectrometry (LC-MS/MS) to analyze epithelial uptake of  
242 nutrients and transfer of these molecules from the lumen of the intestinal epithelium in the top  
243 channel to the underlying basal channel (**Fig. 1a**). We detected 36 metabolites (out of >500  
244 identified) that exhibited lower transport in EED Intestine Chips compared to Healthy Chips  
245 grown in control medium. These included mainly amino acids metabolites, but also metabolites  
246 related to nucleotide, cofactors, lipids, carbohydrates and xenobiotic pathways (**Fig. 4b**; an  
247 extended list of metabolites analyzed can be found in **Supplementary Fig. S6**). Interestingly,  
248 nine of these metabolites were amino acids previously identified as being reduced in serum of  
249 Malawian stunted children<sup>45</sup>. These included essential amino acids (isoleucine, leucine,

250 methionine, phenylalanine, lysine), conditionally essential amino acids (arginine, glycine), and  
251 non-essential amino acids (glutamate, serine).

252 Our LC-MS/MS analysis also revealed 74 metabolites that were secreted by the  
253 intestinal cells as they were absent or at extremely low levels (<5%) in the perfusion medium.  
254 17 of these metabolites were unique to the Healthy Control Chips and included products of  
255 pathways related to metabolism of amino acids (N6,N6,N6-trimethyllysine, 3-  
256 hydroxyisobutyrate, methionine sulfone, N-acetylglutamine, homoarginine, indolelactate,  
257 glutamine, alanine, betaine, imidazole lactate, 3-methylhistidine, 1-methylhistidine),  
258 nucleotides (thymine, 2'-deoxyuridine, 7-methylguanine), xenobiotic metabolism (guaiacol  
259 sulfate), or lipids (3-hydroxy-3-methylglutarate). Interestingly, we also identified 4 metabolites  
260 unique to the EED Chips cultured in control medium, including products of purine nucleotide  
261 metabolism (xanthine), vitamin B6 metabolism (pyridoxal), citric acid cycle /energy metabolism  
262 (alpha-ketoglutarate), and fatty acid metabolism (acetylcarnitine (C2)) (**Fig. 4c**).

263 To assess if the observed differential uptake and metabolism of molecules in the  
264 Intestine Chips were transporter dependent, we quantified uptake of the dipeptide, glycyl-  
265 sarcosine (Gly-Sar) by the epithelial cells in the top channel, and its transfer to the lower  
266 channel using LC-MS/MS. This analysis revealed reduced uptake and transport of Gly-Sar in  
267 nutritionally deficient Healthy Intestine Chips when compared to the same chips cultured in  
268 control medium (**Supplementary Fig. S5**). In addition, these studies confirmed that these  
269 effects were due to transport through the PEPT1 transporter, and not due to passive inter- or  
270 intra-cellular diffusion, as this response could be completely prevented by adding Gly-Gly  
271 dipeptide (1 mM), which is a specific inhibitor of this transporter<sup>46</sup> (**Supplementary Fig. S5**).

## 272 **Altered inflammatory mediators**

273           Altered intestinal inflammation is a key component of EED and our transcriptional  
274 analysis revealed that genes encoding key inflammatory marker proteins, such as lipocalin 2  
275 (LCN2) and regenerating islet-derived protein 3 alpha (REG3A) were upregulated when EED or  
276 Healthy Chips were exposed to nutritional deficiency (**Fig. 1c** and **Supplementary Fig. S7**).  
277 Indeed, when we quantified the expression of nine key intestinal cytokines using a multiplexed  
278 ELISA assay, we detected higher levels of several cytokines (IL-6, ICAM, VCAM, IL-33, MCP-1,  
279 MIP-1 alpha and IL-8) in the epithelial lumen of Healthy -N/-T Intestine Chips compared to the  
280 same chips cultured in control medium (**Fig. 5a**). The antimicrobial peptide Reg3A was also  
281 downregulated by nutritional deficiency in these chips. Interestingly, EED Intestine Chips grown  
282 in complete medium displayed reduced levels of all of the secreted cytokines analyzed, while  
283 their levels were significantly upregulated when these chips were grown in nutritionally  
284 deficient medium (**Fig. 5a**). Similar responses were observed when we analyzed cytokine levels  
285 in the lower parenchymal or vascular channel; however, there significantly higher levels of the  
286 inflammatory cytokines IL-8, IP-10, and MCP-1 were observed (**Fig. 5a**). Interestingly, we found  
287 that Intestine Chips that were not exposed to mechanical peristalsis-like deformation, secreted  
288 lower levels of IL-8 and MCP-1 (**Supplementary Fig. S8**).

289

## 290 **DISCUSSION**

291           Given the importance of studying the pathophysiology and the underlying mechanisms  
292 of EED, and the current lack of human *in vitro* models, this study leveraged the Human Intestine  
293 Chip technology to create an *in vitro* EED model using cells obtained from EED and healthy

294 patient intestinal biopsies. The Intestine Chip offers a unique advantage over other advanced in  
295 vitro models, such as intestinal organoids, because direct access to the two parallel flow  
296 channels of the device enable quantitation of intestinal barrier function as well as  
297 transepithelial absorption and transport that are not possible in static 3D enteroid cultures.  
298 Using this approach, we explored the effect of nutritional deficiencies on the manifestation of  
299 the disease at both the phenotypic and functional levels. Importantly, our results showed that  
300 human Intestine Chips lined by intestinal epithelial cells isolated from organoids derived from  
301 EED patients mimic key features of the transcriptome signature of EED patients, including  
302 upregulation of antimicrobial genes and downregulation of metallothioneins and genes involved  
303 in digestion and metabolism, but only when exposed to nutritional deficiency, which we  
304 modeled by removing niacin and tryptophan from the medium. In contrast, nutritional  
305 deficiency induced similar intestinal villus atrophy, disruption of barrier function, and changes in  
306 amino acid and fatty acid absorption in chips lined by cells from both healthy and EED patients.  
307 Thus, we were able to attribute these various responses specifically to nutritional deficiency, to  
308 genetic or epigenetic changes in the intestinal epithelium, or to a combination of both,  
309 distinctions that have not been possible to make in clinical studies.

310 Malnutrition in EED can be regarded as both a cause and an outcome of the disease. In  
311 this study, we examined the effect of dual deficiency of an essential amino acid tryptophan and  
312 the vitamin niacin (in the form of niacinamide) because of their reported effect on intestinal  
313 development and function, and the suggested correlation between their deficiencies and EED  
314 development<sup>45,47</sup>. Remarkably, we observed a 6-fold increase in number of genes differentially  
315 expressed when we compared the EED Intestine Chips exposed to nutritional deficiency

316 compared to Healthy Chips grown in complete medium. Moreover, many of the affected  
317 pathways were associated with nutritional uptake and cellular energy processing. These results  
318 imply that nutritional deficiency itself leads to derangements in nutritional processing that  
319 create a positive feedback loop, which further worsens the nutritional deficiency in EED  
320 patients.

321 Villus blunting and barrier dysfunction are hallmarks of EED, but also of other intestinal  
322 pathological conditions, such as inflammatory bowel diseases, celiac, diarrhea and small  
323 intestine bacterial overgrowth<sup>48,49</sup>. Indeed, we were able to show in this study that these  
324 phenotypes can manifest because of nutritional deficiencies regardless of whether the  
325 intestinal epithelium was derived from healthy or EED patients. This implies that the villus  
326 blunting and barrier dysfunction observed in EED, may be a response to environmental  
327 conditions, rather than an inherent genetic or developmental feature of this disease. This  
328 finding has high clinical relevance because the intestinal epithelium undergoes continuous  
329 shedding and renewal every 3-5 days; hence, the chronic negative effect of nutritional  
330 deficiencies might explain a fundamental aspect of the malabsorption and poor response to  
331 oral vaccination seen in EED patients. The ability to dissect and assess the factors leading to  
332 villus blunting in EED (as well as in other intestinal conditions) in vitro is a unique capability  
333 enabled by Intestine Chips that support formation of 3D villus-like structures as well as mucus  
334 production and quantification of transepithelial transport, absorption, and secretion.

335 Fat is a macronutrient responsible for 30 to 40% of total caloric intake in children and 20  
336 to 35% in adults, and fatty acid composition has a direct effect on health and development,  
337 including inflammatory status and cognitive development.<sup>50,51</sup> Our transcriptomic analysis was

338 sensitive enough to detect several genes including ApoB that were downregulated in  
339 nutritionally deficient epithelium, and we confirmed that the expression of this molecule is  
340 decreased using immunofluorescence microscopy, and that fatty acid absorption is impaired in  
341 both EED -N/-T and Healthy -N/-T Chips (when compared to their respective controls), using a  
342 fatty acid uptake assay.

343         Given that dietary protein is an important macronutrient directly linked to linear growth  
344 and the results from our transcriptome-wide analysis revealed downregulation of amino acid  
345 transporters in EED Chips, we also conducted a untargeted metabolomic analysis that identified  
346 several amino acids which are significantly reduced in the EED Control Chips when compared to  
347 Healthy Control Chips. More interestingly, we identified metabolites that were secreted by the  
348 intestinal epithelium into the lower channel. Thus, the Intestine chip may be used as a  
349 nutritional and metabolic screening tool where uptake, utilization, and secretion of specific  
350 metabolites by and through the intestinal epithelium can be followed in high resolution and  
351 quantified over time. Moreover, future analysis of molecules released into the lower flow  
352 channel could lead to identification of biomarkers of disease severity and/or progression that  
353 might be detectable in blood.

354         While reduction of intestinal absorptive surface area due to villus blunting caused by  
355 nutritional deficiency will impair nutrient uptake by the intestine, exposure to nutritional  
356 deficiency also directly suppressed expression of multiple genes related to nutrient absorption  
357 specifically in chips lined by cells from EED patients. Thus, these results suggest that nutritional  
358 deficiency has a two-fold effect in these patients, which would likely manifest in a greater  
359 degree of intestinal dysfunction and a more severe EED phenotype. In our study, we also found



360 that EED Intestine Chips exposed to nutritional deficiencies produced greater amounts of  
361 inflammatory cytokines compared to Healthy Chips grown under the same -N/-T conditions.  
362 This is a critical detail as inflamed intestine has higher caloric demands for basic maintenance  
363 and renewal, which could result in a negative caloric balance unable to support catch-up  
364 growth. Furthermore, chronic inflammation may negatively affect the efficacy of oral vaccines  
365 in the EED intestine. As such, it is possible that the lack of catch-up growth in EED children  
366 receiving nutritional intervention is due to current interventions only supplying nutrients aimed  
367 at replenishing the deficiency in tissues responsible for linear growth (bone, muscles). A more  
368 effective approach might be to first administer a diet composition that preferentially promotes  
369 intestinal recovery with new formation of villi and restores increased intestinal absorptive area  
370 before moving to supplementation required for catch-up growth.

371         The unique ability of the Intestine Chips to allow environmental factors (e.g., cell source,  
372 nutrient levels) individually or in combination in a controlled manner and to explore multiple  
373 clinically relevant outcomes, such as cell and tissue morphology, barrier function, nutrients  
374 metabolism and absorption, inflammatory status and transcriptome modifications, enabled us  
375 to distinguish between manifestations more common to multiple intestinal diseases versus  
376 responses that are more unique to EED. For example, we identified the cluster of differentiation  
377 36 (CD36), gene, which has several functions relevant to EED as well as intestinal cancer and  
378 other intestinal diseases (e.g., fatty acid translocase, regulator of inflammation, oxidative stress,  
379 angiogenesis) to be significantly down regulated under nutritional deficiencies in both Healthy  
380 and EED Intestine Chips. Remarkably, our findings relating to EED are directly in line with  
381 recently published clinical data that explored unique signatures of EED affected children

382 compared to healthy controls and children with celiac disease<sup>33</sup>. Thus, this *in vitro* EED model  
383 may be useful for gaining further insight into the pathophysiology of this disease as well as for  
384 development of potent therapeutics. The Intestine Chip also could provide a platform for  
385 personalized medicine and nutrition when cultured with clinical biopsies, enabling personalized  
386 (patient-specific) digestion, absorption, and allergic reactions to be assessed for different  
387 nutrients without putting the patient in danger.

388

## 389 **METHODS**

### 390 ***Organoid cultures and Intestine Chips***

391 Organoids from Healthy donors or EED patients were generated from biopsy samples  
392 collected during exploratory gastroscopy following a procedure previously described<sup>52</sup>. A total  
393 of 3 Healthy and 2 EED donors were used to generate the data in this study (**Supplementary**  
394 **Table 2**). For the Healthy Chips, de-identified endoscopic tissue biopsies were collected from  
395 grossly unaffected (macroscopically normal) areas of the duodenum in patients undergoing  
396 endoscopy for gastrointestinal complaints. Informed consent was obtained at Boston Children's  
397 Hospital from the donors' guardian. All methods were carried out in accordance with the  
398 Institutional Review Board of Boston Children's Hospital (Protocol number IRB-P00000529)  
399 approval. For the EED Chips, de-identified endoscopic tissue biopsies were collected from  
400 affected areas of the duodenum in patients undergoing endoscopy following unsuccessful  
401 educational and nutritional intervention for wasting. Informed consent was obtained at the  
402 household level in a rural district of Matiari, Sind, Pakistan from the donors' guardians. All  
403 methods were carried out in accordance with the AKU Ethical Review Committee's approval

404 (ERC number 3836-Ped-ERC-15). Organoids were kept in complete growth medium<sup>27,52</sup>, and  
405 passaged every 7 days in a 1:4 ratio. Before cell seeding, S-1 Chips (Emulate) were activated  
406 using ER1/2 (Emulate) and UV exposure for 20 minutes. Chips were then coated with 200 µg  
407 ml<sup>-1</sup> collagen I (BD Corning) and 100 µg ml<sup>-1</sup> Matrigel (BD Corning) in serum-free DMEM-F12  
408 (Gibco) for 2 hours at 37 °C. After wash, organoids were broken into smaller fragments using  
409 enzymatic activity (TrypLE, Gibco) and seeded in the luminal upper channel of the chips. They  
410 were then allowed to adhere for 24h before introduction of flow and mechanical deformation  
411 as described before<sup>27</sup>. For the -N/-T treatment, niacinamide and tryptophan were removed  
412 from the basal medium (DMEM-F12, Gibco) used to prepare the expansion culture medium  
413 (used for the luminal and lower channels) and no additional niacinamide was added<sup>27</sup>. After 16-  
414 18 days in culture with continuous flow (60 µl/h) and mechanical deformation (10%, 0.15 Hz),  
415 medium was changed to differentiation medium (serum and Wnt-3A free<sup>27</sup>, and -N/-T free for  
416 the respective group), in the luminal top channel and expansion culture medium in the lower  
417 channel for 4 additional days.

#### 418 ***Microarray sequencing and bioinformatics analysis***

419 Initial microarray experiments were carried out using one healthy donor (n=3 biological  
420 replicates) and one EED donor (n=3 biological replicates) and were reflective of a recent clinical  
421 EED transcriptomic signature derived from a larger population (SEEM study, n=25 healthy  
422 donors, 52 EED donors). Subsequent validation studies were carried out using 1-3 healthy  
423 donors (n=3-9 biological replicates) and 1-2 EED donors (n=3-8 biological replicates) per  
424 experiment. RNA samples were processed using the GeneChip WT PLUS Reagent Kit and  
425 hybridized to Affymetrix Human Clariom D arrays. Samples were pre-processed with SCAN

426 (SCAN.UPC package) and resulting expression values were quantile-normalized within the  
427 experiment, and differential expression analysis was performed with limma<sup>53</sup> R package for  
428 each comparison pair; gene expression values were averaged for each condition. Template  
429 matching was used to extract genes that are differentially expressed between these conditions.  
430 Differential gene expression heatmap analysis was performed using Euclidean distance and  
431 McQuitty's linkage within the R package heatmaply<sup>34</sup>. To normalize values across experiments,  
432 columns were scaled to generate a Z-score. Pathway analysis was performed using the natural  
433 language processing algorithm COMprehensive Multi-omics Platform for Biological  
434 InterpretatiOn (COMP BIO) to generate a holistic, contextual map of the core biological themes  
435 associated with gene expression changes. Enriched concepts associated with differentially  
436 expressed genes were compiled from PubMed abstracts using contextual language processing.  
437 Themes were scored using a complex function that incorporates an empirical p value and a  
438 standard score similar to a Z-score to give a final value representing fold enrichment over a  
439 random clustering as follows: 3-9 = weak relationship, 10-99 = modest relationship, 100-999 =  
440 strong relationship, 1000+ = very strong relationship. A theme map was generated where  
441 themes are represented as nodes and interconnections between themes are represented as  
442 edges with the thickness of an edge relating to the degree of interconnection.

#### 443 ***Immunofluorescence microscopy***

444 Immunofluorescence microscopic imaging was carried out using the following steps: the  
445 apical and basal channels of the chips were gently washed with PBS and fixed with 4%  
446 paraformaldehyde (Electron Microscopy Sciences, Cat#: 157-4) in PBS for 30 min, then washed  
447 twice with PBS and kept at 4°C. The fixed samples were sectioned to 150-250 µm sections using  
448 a vibratome (Leica), and then permeabilized and blocked with 0.1% Triton X-100 solution and

449 10% Donkey serum in PBS, for 30 min at room temperature. Then primary antibody (Apo-B,  
450 Abcam, Cat#:ab20737) was added (1:100 in 1.5% BSA/PBS solution) and incubated overnight at  
451 4 °C, followed by multiple PBS washes. Cells were then incubated with secondary fluorescent  
452 antibody (Invitrogen Cat#:SA5-10038) and Phalloidin (Invitrogen Cat#: A12380) at room  
453 temperature for 60 min and washed with PBS; nuclei were co-stained with hoechst 33342  
454 (Sigma, Cat#: 14533). Microscopy was performed with a laser scanning confocal microscope  
455 (Leica SP5 X MP DMI-6000 or Zeiss TIRF/LSM 710).

456

#### 457 ***Paracellular permeability measurements***

458 To assess paracellular permeability, 50 µg ml<sup>-1</sup> of Cascade blue (5.9 kDa; Thermo Fisher,  
459 C687) was introduced to the luminal channel (at 60 ml h<sup>-1</sup>). After flowing over-night to saturate  
460 the microfluidic channels, outflows were discarded and collection for measurements started for  
461 ~24 hours. The fluorescence intensities (390nm/420nm) of the top and bottom channel  
462 effluents were measured using a multimode plate reader (BioTek NEO). The apical to-  
463 basolateral flux of the paracellular marker was calculated using the following equation:  
464  $P_{app} = (dQ/dt) / AdC$ .  $dQ/dt$  (g s<sup>-1</sup>) is molecular flux,  $A$  (cm<sup>2</sup>) is the total area of diffusion and  $dC$   
465 (mg ml<sup>-1</sup>) is the average gradient.

#### 466 ***Mucus assessment***

467 Mucus was visualized using a WGA–Alexa Fluor 488 conjugate (Thermo Fisher Scientific,  
468 Cat#: W11261) for live cell imaging, as described previously<sup>25</sup> with some modifications. Briefly  
469 WGA solution (25 µg ml<sup>-1</sup> in HBSS) was flowed through the epithelium channel for 30 minutes  
470 and then washed with continuous flow of HBSS for 30 min. Intestine chips were then cut  
471 sideways parallel to the length of the channel and imaged with an epifluorescence microscope  
472 (Zeiss Axio Observer Z1) with 5x objective.

473 ***Fatty Acid Uptake***

474 Chips were starved for 1 hour by replacing the luminal and lower channel media with  
475 HBSS. Then, fluorescently-labelled dodecanoic acid combined with a quencher (to eliminate any  
476 unspecific signal), were added according to the manufacturer instructions (BioVision, Cat#:  
477 K408) to the luminal upper channel of the intestine chips. The entire length of the channels was  
478 then imaged with an epifluorescence microscope (Ex/Em = 488/523 nm, Zeiss Axio Observer Z1)  
479 with 5x objective, at 5, 10, 30 and 60 minutes.

480 ***Metabolomics***

481 Medium in the lower channel of the chips was changed to HBSS and flowed for 30  
482 minutes to clear any residues. Then collection of outflows was conducted over 5 hours. Samples  
483 were frozen immediately after collection (-80 °C), and submitted for LC-MS/MS analysis. The  
484 Metabolon global metabolomics platform was used to measure biochemicals in cell and media  
485 samples. Samples were prepared using the automated MicroLab STAR® system from Hamilton  
486 Company. Several recovery standards were added prior to the first step in the extraction  
487 process for QC purposes. To remove protein, dissociate small molecules bound to protein or  
488 trapped in the precipitated protein matrix, and to recover chemically diverse metabolites,  
489 proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills  
490 GenoGrinder 2000) followed by centrifugation. The resulting extract was divided into five  
491 fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with  
492 positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with  
493 negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and  
494 one sample was reserved for backup. Samples were placed briefly on a TurboVap® (Zymark) to

495 remove the organic solvent. Raw data was extracted, peak-identified and QC processed using  
496 Metabolon's hardware and software.

497 Beginning with the OrigScale values from Metabolon, which are normalized in terms of  
498 raw area counts, we calculated total ion count in outflow to visualize sample-wise variance.  
499 Next, we normalized each sample by its total ion count and rescaled each metabolite values by  
500 dividing each metabolite by its root mean square. We visualized metabolite abundance using a  
501 heatmap. Statistical analysis and heatmap generation was performed using R (R Foundation for  
502 Statistical Computing, Vienna, Austria). We performed differential expression analysis by using  
503 the limma<sup>53</sup> R package (v3.32.10) was used to fit a linear model to the data. Log<sub>2</sub> fold change, *p*-  
504 value and adjusted *p*-value were calculated for each comparison using an unmoderated  
505 Student's t-test and the FDR method for multiple testing correction<sup>54</sup>. Adjusted *p*-values are  
506 shown in the volcano plots. To assess transporter mediated uptake and transfer from the  
507 luminal upper channel to the lower channel, glycyl-sarcosine (Gly-Sar, 1 mM, Sigma) alone or in  
508 combination with the specific PEPT1 transporter inhibitor Gly-Gly dipeptide (1 mM, Sigma),  
509 were added to luminal medium and their abundance in the lower channel outflow was  
510 assessed.

### 511 ***Statistical analysis***

512 Each Intestine Chip was used as a biological repeat for one terminal assay. Either a  
513 Student's t-test or 2-way ANOVA was performed to determine statistical significance, as  
514 indicated in the figure legends (error bars indicate standard error of the mean (SEM); *p*-values <  
515 0.05 were considered to be significant).

516

517 **ACKNOWLEDGMENTS**

518           This research was sponsored by funding from the Bill and Melinda Gates Foundation  
519 (independent support to D.E.I.), NIH award DK119488 (to D.T.B), and the Wyss Institute for  
520 Biologically Inspired Engineering (to D.E.I). This work was conducted with the support of a KL2  
521 award (an appointed KL2 award) from Harvard Catalyst | The Harvard Clinical and Translational  
522 Science Center (National Center for Advancing Translational Sciences, National Institutes of  
523 Health Award KL2 TR002542). The content is solely the responsibility of the authors and does  
524 not necessarily represent the official views of Harvard Catalyst, Harvard University and its  
525 affiliated academic healthcare centers, or the National Institutes of Health.

526 **AUTHOR CONTRIBUTIONS**

527           A.B, C.W.F, G.G and D.E.I. designed the research. A.B, C.W.F, B.S, W.C, A.N, N.L, S.S, S.K,  
528 and S.J.F performed experiments. A.B, C.W.F, W.C, R.K.P, D.M.C, A.P, J.G, R.P.B, G.G and D.E.I.  
529 analysed and interpreted the data. D.T.B. established and prepared human Healthy organoids.  
530 J.I and A.A established and prepared human EED organoids. L.A.D and S.R.M provided the  
531 clinical data. A.B, C.W.F and D.E.I. wrote the Article with input from G.G. All authors reviewed,  
532 discussed and edited the manuscript.

533 **COMPETING INTERESTS**

534           D.E.I. holds equity in Emulate, Inc., consults for the company and chairs its scientific  
535 advisory board.

536 **DATA AVAILABILITY STATEMENT**

537           Organ chip microarray data that support the findings of this study have been deposited  
538 in Gene Expression Omnibus (GEO) with the accession codes to be determined prior to



539 publication. Clinical mRNASeq data referenced as a comparison are deposited in Gene  
540 Expression Omnibus under accession number [GSE159495](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159495). Unique biological materials used in  
541 this study are available from the corresponding author on reasonable request.

542

## 543 REFERENCES


- 544 1 Kosek, M. *et al.* Assessment of environmental enteropathy in the MAL-ED cohort study:  
545 theoretical and analytic framework. *Clin Infect Dis* **59 Suppl 4**, S239-247, doi:10.1093/cid/ciu457  
546 (2014).
- 547 2 Harper, K. M., Mutasa, M., Prendergast, A. J., Humphrey, J. & Manges, A. R. Environmental  
548 enteric dysfunction pathways and child stunting: A systematic review. *PLoS Negl Trop Dis* **12**,  
549 e0006205, doi:10.1371/journal.pntd.0006205 (2018).
- 550 3 Yu, J. *et al.* Environmental Enteric Dysfunction Includes a Broad Spectrum of Inflammatory  
551 Responses and Epithelial Repair Processes. *Cell Mol Gastroenterol Hepatol* **2**, 158-174 e151,  
552 doi:10.1016/j.jcmgh.2015.12.002 (2016).
- 553 4 Fahim, S. M., Das, S., Gazi, M. A., Mahfuz, M. & Ahmed, T. Association of intestinal pathogens  
554 with faecal markers of environmental enteric dysfunction among slum-dwelling children in the  
555 first 2 years of life in Bangladesh. *Trop Med Int Health* **23**, 1242-1250, doi:10.1111/tmi.13141  
556 (2018).
- 557 5 Oria, R. B. *et al.* Early-life enteric infections: relation between chronic systemic inflammation and  
558 poor cognition in children. *Nutr Rev* **74**, 374-386, doi:10.1093/nutrit/nuw008 (2016).
- 559 6 Haghghi, P. & Wolf, P. L. Tropical sprue and subclinical enteropathy: a vision for the nineties.  
560 *Crit Rev Clin Lab Sci* **34**, 313-341, doi:10.3109/10408369708998096 (1997).
- 561 7 Korpe, P. S. & Petri, W. A., Jr. Environmental enteropathy: critical implications of a poorly  
562 understood condition. *Trends Mol Med* **18**, 328-336, doi:10.1016/j.molmed.2012.04.007 (2012).
- 563 8 Crane, R. J., Jones, K. D. & Berkley, J. A. Environmental enteric dysfunction: an overview. *Food*  
564 *Nutr Bull* **36**, S76-87, doi:10.1177/156482651503615113 (2015).
- 565 9 Manary, M. J. *et al.* Perturbed zinc homeostasis in rural 3-5-y-old Malawian children is  
566 associated with abnormalities in intestinal permeability attributed to tropical enteropathy.  
567 *Pediatr Res* **67**, 671-675, doi:10.1203/PDR.0b013e3181da44dc (2010).

- 568 10 Chen, P. *et al.* Association of vitamin A and zinc status with altered intestinal permeability:  
569 analyses of cohort data from northeastern Brazil. *J Health Popul Nutr* **21**, 309-315 (2003).
- 570 11 van der Merwe, L. F. *et al.* Long-chain PUFA supplementation in rural African infants: a  
571 randomized controlled trial of effects on gut integrity, growth, and cognitive development. *Am J*  
572 *Clin Nutr* **97**, 45-57, doi:10.3945/ajcn.112.042267 (2013).
- 573 12 McKay, S., Gaudier, E., Campbell, D. I., Prentice, A. M. & Albers, R. Environmental enteropathy:  
574 new targets for nutritional interventions. *Int Health* **2**, 172-180, doi:10.1016/j.inhe.2010.07.006  
575 (2010).
- 576 13 Louis-Auguste, J. *et al.* High dose multiple micronutrient supplementation improves villous  
577 morphology in environmental enteropathy without HIV enteropathy: results from a double-blind  
578 randomised placebo controlled trial in Zambian adults. *BMC Gastroenterol* **14**, 15,  
579 doi:10.1186/1471-230X-14-15 (2014).
- 580 14 Hashimoto, T. *et al.* ACE2 links amino acid malnutrition to microbial ecology and intestinal  
581 inflammation. *Nature* **487**, 477-481, doi:10.1038/nature11228 (2012).
- 582 15 Guerrant, R. L. *et al.* Biomarkers of Environmental Enteropathy, Inflammation, Stunting, and  
583 Impaired Growth in Children in Northeast Brazil. *PLoS One* **11**, e0158772,  
584 doi:10.1371/journal.pone.0158772 (2016).
- 585 16 Semba, R. D. *et al.* Environmental Enteric Dysfunction is Associated with Carnitine Deficiency  
586 and Altered Fatty Acid Oxidation. *EBioMedicine* **17**, 57-66, doi:10.1016/j.ebiom.2017.01.026  
587 (2017).
- 588 17 Moehn, S., Pencharz, P. B. & Ball, R. O. Lessons learned regarding symptoms of tryptophan  
589 deficiency and excess from animal requirement studies. *J Nutr* **142**, 2231S-2235S,  
590 doi:10.3945/jn.112.159061 (2012).
- 591 18 Council, N. R. in *Recommended Dietary Allowances: 10th Edition The National Academies*  
592 *Collection: Reports funded by National Institutes of Health* (National Academies Press (US),  
593 1989).
- 594 19 Li, J. *et al.* Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid  
595 receptor 1 activation. *EMBO Mol Med* **9**, 571-588, doi:10.15252/emmm.201606987 (2017).
- 596 20 Brown, E. M. *et al.* Diet and specific microbial exposure trigger features of environmental  
597 enteropathy in a novel murine model. *Nat Commun* **6**, 7806, doi:10.1038/ncomms8806 (2015).

- 598 21 Herland, A. *et al.* Quantitative prediction of human pharmacokinetic responses to drugs via  
599 fluidically coupled vascularized organ chips. *Nat Biomed Eng* **4**, 421-436, doi:10.1038/s41551-  
600 019-0498-9 (2020).
- 601 22 Chou, D. B. *et al.* On-chip recapitulation of clinical bone marrow toxicities and patient-specific  
602 pathophysiology. *Nat Biomed Eng* **4**, 394-406, doi:10.1038/s41551-019-0495-z (2020).
- 603 23 Park, T. E. *et al.* Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier  
604 function and shuttling of drugs and antibodies. *Nat Commun* **10**, 2621, doi:10.1038/s41467-019-  
605 10588-0 (2019).
- 606 24 Jang, K. J. *et al.* Reproducing human and cross-species drug toxicities using a Liver-Chip. *Sci*  
607 *Transl Med* **11**, doi:10.1126/scitranslmed.aax5516 (2019).
- 608 25 Jalili-Firoozinezhad, S. *et al.* A complex human gut microbiome cultured in an anaerobic  
609 intestine-on-a-chip. *Nat Biomed Eng* **3**, 520-531, doi:10.1038/s41551-019-0397-0 (2019).
- 610 26 Musah, S., Dimitrakakis, N., Camacho, D. M., Church, G. M. & Ingber, D. E. Directed  
611 differentiation of human induced pluripotent stem cells into mature kidney podocytes and  
612 establishment of a Glomerulus Chip. *Nat Protoc* **13**, 1662-1685, doi:10.1038/s41596-018-0007-8  
613 (2018).
- 614 27 Kasendra, M. *et al.* Development of a primary human Small Intestine-on-a-Chip using biopsy-  
615 derived organoids. *Sci Rep* **8**, 2871, doi:10.1038/s41598-018-21201-7 (2018).
- 616 28 Kim, H. J., Li, H., Collins, J. J. & Ingber, D. E. Contributions of microbiome and mechanical  
617 deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. *Proc*  
618 *Natl Acad Sci U S A* **113**, E7-15, doi:10.1073/pnas.1522193112 (2016).
- 619 29 Bhatia, S. N. & Ingber, D. E. Microfluidic organs-on-chips. *Nat Biotechnol* **32**, 760-772,  
620 doi:10.1038/nbt.2989 (2014).
- 621 30 Huh, D. *et al.* Reconstituting organ-level lung functions on a chip. *Science* **328**, 1662-1668,  
622 doi:10.1126/science.1188302 (2010).
- 623 31 McElroy, S. J. *et al.* The ErbB4 ligand neuregulin-4 protects against experimental necrotizing  
624 enterocolitis. *Am J Pathol* **184**, 2768-2778, doi:10.1016/j.ajpath.2014.06.015 (2014).
- 625 32 Bernard, J. K., McCann, S. P., Bhardwaj, V., Washington, M. K. & Frey, M. R. Neuregulin-4 is a  
626 survival factor for colon epithelial cells both in culture and in vivo. *J Biol Chem* **287**, 39850-  
627 39858, doi:10.1074/jbc.M112.400846 (2012).

- 628 33 Haberman, Y. *et al.* Mucosal Genomics Implicate Lymphocyte Activation and Lipid Metabolism in  
629 Refractory Environmental Enteric Dysfunction. *Gastroenterology* **160**, 2055-2071 e2050,  
630 doi:10.1053/j.gastro.2021.01.221 (2021).
- 631 34 Galili, T., O'Callaghan, A., Sidi, J. & Sievert, C. heatmaply: an R package for creating interactive  
632 cluster heatmaps for online publishing. *Bioinformatics* **34**, 1600-1602,  
633 doi:10.1093/bioinformatics/btx657 (2018).
- 634 35 Kelly, P. *et al.* Responses of small intestinal architecture and function over time to  
635 environmental factors in a tropical population. *Am J Trop Med Hyg* **70**, 412-419 (2004).
- 636 36 Campbell, D. I. *et al.* Chronic T cell-mediated enteropathy in rural west African children:  
637 relationship with nutritional status and small bowel function. *Pediatr Res* **54**, 306-311,  
638 doi:10.1203/01.PDR.0000076666.16021.5E (2003).
- 639 37 Campbell, D. I., Elia, M. & Lunn, P. G. Growth faltering in rural Gambian infants is associated with  
640 impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation. *J*  
641 *Nutr* **133**, 1332-1338, doi:10.1093/jn/133.5.1332 (2003).
- 642 38 Tyska, M. J. *et al.* Myosin-1a is critical for normal brush border structure and composition. *Mol*  
643 *Biol Cell* **16**, 2443-2457, doi:10.1091/mbc.e04-12-1116 (2005).
- 644 39 In, J. *et al.* Enterohemorrhagic *Escherichia coli* reduce mucus and intermicrovillar bridges in  
645 human stem cell-derived colonoids. *Cell Mol Gastroenterol Hepatol* **2**, 48-62 e43,  
646 doi:10.1016/j.jcmgh.2015.10.001 (2016).
- 647 40 Wu, G. Dietary protein intake and human health. *Food Funct* **7**, 1251-1265,  
648 doi:10.1039/c5fo01530h (2016).
- 649 41 Nyaradi, A., Li, J., Hickling, S., Foster, J. & Oddy, W. H. The role of nutrition in children's  
650 neurocognitive development, from pregnancy through childhood. *Front Hum Neurosci* **7**, 97,  
651 doi:10.3389/fnhum.2013.00097 (2013).
- 652 42 Hurley, K. M., Yousafzai, A. K. & Lopez-Boo, F. Early Child Development and Nutrition: A Review  
653 of the Benefits and Challenges of Implementing Integrated Interventions. *Adv Nutr* **7**, 357-363,  
654 doi:10.3945/an.115.010363 (2016).
- 655 43 Perkins, J. M., Subramanian, S. V., Davey Smith, G. & Ozaltin, E. Adult height, nutrition, and  
656 population health. *Nutr Rev* **74**, 149-165, doi:10.1093/nutrit/nuv105 (2016).
- 657 44 Nakajima, K. *et al.* Apolipoprotein B-48: a unique marker of chylomicron metabolism. *Adv Clin*  
658 *Chem* **64**, 117-177 (2014).

- 659 45 Semba, R. D. *et al.* Child Stunting is Associated with Low Circulating Essential Amino Acids.  
660 *EBioMedicine* **6**, 246-252, doi:10.1016/j.ebiom.2016.02.030 (2016).
- 661 46 Zietek, T., Rath, E., Haller, D. & Daniel, H. Intestinal organoids for assessing nutrient transport,  
662 sensing and incretin secretion. *Sci Rep* **5**, 16831, doi:10.1038/srep16831 (2015).
- 663 47 Louis-Auguste, J. *et al.* Tryptophan, glutamine, leucine, and micronutrient supplementation  
664 improves environmental enteropathy in Zambian adults: a randomized controlled trial. *Am J Clin*  
665 *Nutr* **110**, 1240-1252, doi:10.1093/ajcn/nqz189 (2019).
- 666 48 Elli, L. *et al.* Small bowel villous atrophy: celiac disease and beyond. *Expert Rev Gastroenterol*  
667 *Hepatol* **11**, 125-138, doi:10.1080/17474124.2017.1274231 (2017).
- 668 49 Antoni, L., Nuding, S., Wehkamp, J. & Stange, E. F. Intestinal barrier in inflammatory bowel  
669 disease. *World J Gastroenterol* **20**, 1165-1179, doi:10.3748/wjg.v20.i5.1165 (2014).
- 670 50 Simopoulos, A. P. The importance of the ratio of omega-6/omega-3 essential fatty acids. *Biomed*  
671 *Pharmacother* **56**, 365-379, doi:10.1016/s0753-3322(02)00253-6 (2002).
- 672 51 Stonehouse, W. Does consumption of LC omega-3 PUFA enhance cognitive performance in  
673 healthy school-aged children and throughout adulthood? Evidence from clinical trials. *Nutrients*  
674 **6**, 2730-2758, doi:10.3390/nu6072730 (2014).
- 675 52 Sato, T. *et al.* Long-term expansion of epithelial organoids from human colon, adenoma,  
676 adenocarcinoma, and Barrett's epithelium. *Gastroenterology* **141**, 1762-1772,  
677 doi:10.1053/j.gastro.2011.07.050 (2011).
- 678 53 Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and  
679 microarray studies. *Nucleic Acids Res* **43**, e47, doi:10.1093/nar/gkv007 (2015).
- 680 54 Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful  
681 Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B (Methodological)*  
682 **57**, 289-300, doi:<https://doi.org/10.1111/j.2517-6161.1995.tb02031.x> (1995).
- 683




684  
 685 **Figure 1. a)** A schematic representation of Small Intestine chips. **b)** When compared to Healthy  
 686 Chips, the EED transcriptome consists of 287 differentially expressed genes (red; FDR < 0.05 and




687 fold change  $\geq 1.5$ ). Exposure of Healthy and EED Chips to -N/-T media resulted in an increased  
688 number of differentially expressed genes with 690 (yellow) and 969 genes (blue) respectively.  
689 Of these 307 genes were differentially expressed in both Healthy and EED Chips exposed to  
690 nutritional deficiency (yellow and blue). 71 genes were differentially expressed in EED Chips  
691 when compared to Healthy Chips in control media that are further affected by the addition of  
692 nutritionally deficient media (blue and red). n = 3 chips for each condition. **c)** A comparison of  
693 the 50 most up- and 50 most downregulated genes from the clinical EED signature with Healthy  
694 or EED Chip gene expression is depicted as a heatmap (red = upregulation, blue =  
695 downregulation) showing that EED -N/-T has the closest hierarchical relationship to the clinical  
696 EED signature. The comparison for EED -N/-T to Healthy Con is similar and shown in  
697 **Supplementary Fig. S9**. Ten dendrogram gene clusters were also defined and the corresponding  
698 roots enumerated. n = 3 chips for each condition. **d)** Of the top 9 upregulated genes in the  
699 clinical EED signature, 6 were also upregulated when EED chips were exposed to -N/-T media. n  
700 = 3 chips for each condition. **e)** Functional pathway analysis was performed using the  
701 contextual language processing program COmprehensive Multi-omics Platform for Biological  
702 InterpretatiOn (COMP BIO). The spatial map depicts themes related to differentially expressed  
703 genes as nodes with interconnections depicted as edges whose thickness relates to the degree  
704 of interconnectedness. The themes were also ranked according to a score representing fold  
705 enrichment over random clustering. n = 3 chips for each condition.

706





708 **Figure 2. a)** Differential Interference Contrast (DIC) imaging of Intestine chips, top-down view.  
709 Scale bar= 50  $\mu\text{m}$ . Representative images. **b)** Immunofluorescence cross section micrographs  
710 showing villus like structures in the Intestine Chips. Yellow- phalloidin, Blue- Hoechst. Scale bar  
711 = 50  $\mu\text{m}$ . Representative image. **c)** Villus like structures height differences between Con and -  
712 N/-T, Healthy and EED Intestine Chips. Healthy,  $p < 0.000001$ , EED,  $p = 0.000685$ . Each symbol  
713 on the graph represent an average of 4 to 5 measurement points (membrane to top of the villi)  
714 measured in two to three cross section images of Intestine Chip, at least 2 chips per condition  
715 were used. Two different Healthy donors and one EED donor were used. **d)**  
716 Immunofluorescence longitudinal section micrographs showing mucus layer in the Intestine  
717 Chips, stained with Alexa 488 conjugated lectin. Scale bar= 250  $\mu\text{m}$ . Representative images. **e)**  
718 Apparent permeability ( $P_{app}$ ), differences between Con and -N/-T, Healthy and EED Intestine  
719 Chips. Healthy,  $p = 0.000005$ ; EED,  $p = 0.001382$ .  $n = 9$  for Healthy Intestine Chips and  $n = 8$  for EED  
720 Intestine Chips.




721

722 **Figure 3. a)** Transcriptional pathway analysis revealed a strong theme of downregulation for

723 genes related to fatty acid uptake when EED Chips were exposed to -N/-T media. This included

724 a 9.8-fold downregulation of the receptor CD36 (FDR < 0.001), a 10.2-fold downregulation of  
725 ApoB (FDR <0.001) and an 8.2-fold downregulation of ABCC2 (FDR <0.001). There was a similar  
726 trend towards downregulation when Healthy Chips were exposed to -N/-T media, but most  
727 gene changes did not reach statistical significance. n = 3 chips for each condition. **b)** Differences  
728 in ApoB corrected total fluorescence expression in Con and -N/-T Healthy and EED Intestine  
729 Chips. Healthy, not significant, EED,  $p=0.012284$ . Each symbol on the graph represent an  
730 average of corrected total fluorescence expression from 3 different measurement areas of  
731 Intestine Chips cross sections, from at least 2 chips per condintion. **c)** Differences in  
732 fluorescently-labeled dodecanoic fatty acid uptake by the Intestine Chips at 5, 10, 30 and 60  
733 minute time points. \*  $p=0.0396$ , \*\*\*  $p\leq 0.0008$ , \*\*\*\*  $p<0.0001$ . For each time point, 7 images  
734 covering the entire area of a representative chip from each condition were used to calculate  
735 the corrected total fluorescence expression.  
736




737


738 **Figure 4. a)** Amino acid processing and transport was among the strongly downregulated

739 themes when EED Chips were exposed to -N/T media. This included a 6.2-fold downregulation


740 of MEP1B (FDR < 0.001), a 4.4-fold downregulation of SLC2A2 and a 3.3-fold downregulation of  
741 XPNPEP2 (FDR < 0.01). There was occasional downregulation of these genes when Healthy  
742 Chips were exposed to -N/-T media, but none that achieved statistical significance. n = 3 chips  
743 for each condition. **b)** Heatmap showing 36 metabolites up-taken and transferred from the  
744 luminal medium to the lower channel of the Intestine Chips at higher abundance in the Healthy  
745 vs EED chips. n=3 for each condition. **c)** Venn diagram showing the number of common and  
746 unique metabolites secreted by the cells in Intestine Chips.



747  
748 **Figure 5. a)** Heatmaps showing differential expression of 9 cytokines secreted into the lumen or  
749 lower channel of the Con or -N/-T, Healthy and EED Intestine Chips and quantified using a bead  
750 based multiplexed ELISA. Color coded scale represents Log<sub>2</sub> fold change in expression. n=3 to 6  
751 for each condition.



752  
 753 **Supplementary Figure 1.** A Venn diagram representation showing overlap of differentially  
 754 regulated genes ( $p$ -value < 0.01, fold change > 2) for EED and Healthy Chips exposed to  
 755 complete and nutritionally deficient media. Affected genes are listed and genes that were also  
 756 differentially expressed in the clinical EED gene signature are in bold.  $n = 3$  chips for each  
 757 condition.



758

759 **Supplementary Figure 2.** Transcriptional pathway analysis revealed a strong theme of


760 downregulation for genes related to brush border localization and structural integrity when EED

761 Chips were exposed to -N/-T media. This included a 3.6-fold downregulation of CDHR2 (FDR <

762 0.01) and more modest downregulation of MYO1A (1.7-fold, FDR <0.01) and CDHR5 (1.6-fold,

763 FDR < 0.05). n = 3 chips for each condition.






764

765 **Supplementary Figure 3.** SEM views of the apical surface in the Intestine Chip comparing the  
766 morphology of Control and -N/-T treated Healthy chips. Scale bar, 20 μm (left) and 2 μm (right).


767 Representative images.





768

769 **Supplementary Figure 4.** a) Heatmap showing up and down regulated nutrients uptake and  
770 metabolism related genes in Control and -N/-T Healthy Chips. b) Heatmap showing all ~ 23000  
771 up and down regulated genes in control and -N/-T healthy chips. n=4 for each condition.



772


773 **Supplementary Figure 5.** Calculated apparent permeability (Papp) of Gly-Sar dipeptide transfer

774 from the lumen to the lower channel showing differences between Con and -N/-T, in Healthy

775 Intestine Chips, in the presence or absence of Gly-Gly inhibitor. Con vs -N/-T,  $p=0.0022$ , with vs

776 without inhibitor  $p=0.000003$ .  $n=3$  for each condition.






780

781 **Supplementary Figure 7. a)** Secreted REG3A levels measured in Intestine Chips luminal

782 outflows. Healthy Chip,  $p=0.029$ , EED Chip,  $p<0.000001$ .  $n=3$  to 6 for each condition. **b)** Lipocalin

783 2 (LCN2) relative expression measured by ELISA.



784

785 **Supplementary Figure 8.** Secreted IL-8 levels measured in the Intestine Chips lower channel


786 outflows, with and without peristalsis (P). Healthy Chip Con + P vs -N/-T + P,  $p=0.000148$ ; -N/-T

787 + P vs -N/-T no P,  $p=0.029388$ . EED Chip Con + P vs -N/-T + P,  $p=0.000129$ ; -N/-T + P vs -N/-T

788 no P,  $p=0.016852$ . Secreted MCP-1 levels measured in the Intestine Chips lower channel



795 upregulation, blue = downregulation) showing the expression pattern for EED Chips in -N/-T  
796 media vs Healthy Chips in control media. n = 3 chips for each condition.



797  
798 **Supplementary Figure 10.** Transcriptional pathway analysis revealed a strong theme of  
799 downregulation for genes related to fatty acid absorption and processing when EED Chips were  
800 exposed to -N/-T media. This included a 4.7-fold downregulation of CIDEA (FDR < 0.0001), a 4.9-  
801 fold downregulation of CREB3L3 (FDR < 0.001) and a 7.7-fold downregulation of PCK1 (FDR <  
802 0.0001). n = 3 chips for each condition.